Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning gentlemen
Just got back from Colorado officers of company hid
Hello
Good one
Clearwater fl Hair infomercial frog adds kevin harrington,st pete,clearwater curt platt sarasota .sherman mazur ,they are all together
https://www.fbi.gov/losangeles/press-releases/2013/fourteen-arrested-for-market-manipulation-schemes-that-caused-thousands-of-investors-to-lose-more-than-30-million
kevin harrington is a thief his partner chris phillips from midtown partners got arrested was in jail then house arrest
you can look it up on the internet
no its curt platt and nick salerno
michael littmman attorney oh boy
Pump and dump
CannapharmaRx, aka Golden Dragon Holding Company (symbol GDHC) and its CFO sued by Co-Founder, major Shareholder, and Member ...
Date : 11/04/2014 @ 2:46PM
Source : PR Newswire (US)
Stock : Golden Dragon Holding Co. (QB) (GDHC)
Quote : 3.53 0.0 (0.00%) @ 8:05AM
CannapharmaRx, aka Golden Dragon Holding Company (symbol GDHC) and its CFO sued by Co-Founder, major Shareholder, and Member ...
Print
Alert
Golden Dragon Holding Co. (QB) (USOTC:GDHC)
Intraday Stock Chart
Today : Wednesday 5 November 2014
Click Here for more Golden Dragon Holding Co. (QB) Charts.
TAMPA, Fla., Nov. 4, 2014 /PRNewswire/ -- Gary Cohen, BSPharm, RPh, the founder and visionary of the CannapharmaRx, Inc. and the National Association of Cannabis Pharmacy (NACPRx.net), filed a lawsuit against the corporation, and its CFO, Mr. Gary Herick.
The suit alleges that Gary Herick, and the company's board of directors breached their fiduciary responsibility to the company, its employees and shareholders. Additional counts alleged in the suit include equitable accounting, breach of duty of good faith, duty of loyalty & duty of care, abuse of control, conversion, misappropriation of business opportunities, and defalcation.
Cohen filed an additional derivative suit on behalf of the CannapharmaRx Corporation. The lawsuit alleges that the Board's failure to remove Herick, after he would not provide shareholders with any accounting or financial documents is a breach of their fiduciary duties. Cohen alleges that the Board ignored requests for Herick's resignation, as well as other requests for accountability that were in the best interests of its shareholders. The suit further alleges that the wrongful conduct was not due to an honest error in judgment, but rather to Defendant's gross mismanagement, bad faith and/or reckless disregard of the rights and interests of the corporation, its shareholders, and for acting without the reasonable and ordinary care which they owed the corporation.
Cohen has also sued for breach of written contract, breach of oral contract, and wrongful termination & retaliatory personnel action in violation of Florida's Whistleblower Act at section 448.102(3), Florida Statutes.
For a full copy of the suit, see Hillsborough Court # 14-CA-010970
hi nick go to jail you thief you lets talk about how you robbed the neighborhood and how you paid off people to buy the shares like curt platt john nole and so on lol in the mean time have you paid your taxes lately oh well nicky drop dead you thief How are the dead people stock transfers thAT YOU DID IN HAIR
nick phillip offil salerno
nick baybreeze idigi salerno
hi nick when everyone finds out that your are the largest
shareholder in this company and your track record and how much you paid for your position .and who you really are lets not forget about your cousin paul price
Hey Nick at bdinterational you know my mission dont you
I heard you are trying to sell a million shares at 3 cents lol
You could not give them away
Hey Nick at bdinterational you know my mission dont you
I heard you are trying to sell a million shares at 3 cents lol
You could not give them away
google this today Crocs co-founder caught driving drunk, blames it on Taylor Swift Maybe they CAN HIRE HIM TO RUN THIS COMPANY.
LOL
hanging in for what call up who ever told you about the stock and ask them how many free trading shares are registered now and you tell me? Why this is a good investment .Look at the ceo last company!
hey big dog want to come out and play come on out and lets see
nick@bdinternational
nick peter burni thief
goood morning sophisticated investors .
Ask who The rest are tune in .You cant hide .You are being watched .Call the management
.”
.
Talked to management Nick Salerno 1st Base share holder 30 million Shares failer to disclose Over 5% Lets read about him
we are going to discuss the real people behind the deal.
Come on out behind the curtain .You are on center stage now.Come on come on out.
And today we are going to discuss the real people behind the deal.
Come on out behind the curtain .You are on center stage now.Come on come on out.
what do. you have inside info?there are 200 million free trading shares .call signature stock transfer and ask .They are in plano texas.
I dont think you are ? Just smells a little fishy .
Enjoy your weekend .Have a pleasent one
so they hired an add agency ?what does that mean?makes the stock look pretty i can only go by amstem i think its under a penny
amst pk
Regenerative Medicine Is the Future of Stem Cell Science and AmStem Is Leading the Way
SAN FRANCISCO, CA--(Marketwire - September 1, 2010) - AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today the appointment of Dwight Brunoehler as president of the company.
Brunoehler will direct day to day operations with responsibility for advancing the company's business plan, including building an expert medical advisory board, commercial launch of its stem cell based cosmeceutical products and working with AmStem's Korean facility, Histostem, to help create and expand international business and scientific opportunities.
Brunoehler has been working in the cord blood area since 1995 when he established one of the world's first and largest umbilical cord blood banks. This included setting up the first and only nationwide system that enabled expectant mothers to donate their babies' cord blood stem cells from anywhere in the Continental United States. He worked with representatives from Illinois and Wisconsin to draft the first legislation to bring awareness and education to potential donors. Through his committee work with numerous worldwide organizations, Brunoehler has been responsible for numerous unique research and development opportunities including technology licensing in Greece, India and Thailand. He has been a sought after speaker around the world as he continues to share his passion for and knowledge of the field.
AmStem Director Rick Van Den Toorn said, "We have been working with Dwight for the past few months and are pleased that we were able to reach an agreement for him to join us in our efforts to expand our extensive line of stem cell products and services worldwide. Dwight is one of the most respected leaders in the stem cell arena. His global accomplishments are nearly legendary and he brings a new dimension and vast experience to our team. He commands respect with the scientific community and the cosmeceutical area of our business. His experience will be highly attractive to the investment community and his ability to effectively speak out on our behalf will be an enormous benefit in a variety of ways."
Brunoehler said, "I could not possibly be more excited and honored to become a part of this world class organization and to have the opportunity to interface with Dr. Han and his team in Korea. When I entered the stem cell science field 16 years ago, bone marrow transplants using cord blood as a stem cell source were just being recognized. Within the past six years cord blood transplants have taken their place in mainstream clinical treatment. Regenerative medicine is well into the cycle of becoming a mainstream clinical treatment from cosmeceutical use to solid organ regeneration. Regenerative medicine is the future of stem cell science and AmStem is leading the way."
"The company is now wrapping up the accounting challenge of merging Histostem into AmStem. The process has proven to be more arduous than originally thought. However KPMG is making excellent progress and I am confident we will return to fully reporting status by early in the fourth quarter.
"In addition to restoring AmStem's position as a fully reporting company, I have several priorities as president. I expect to announce shortly a new Scientific and Medical Board of Advisors. The announcement of this group will substantially underscore the seriousness with which our company must be taken.
"We are moving to get product into the market and build our revenue stream. I have no doubt that SteMixx and other cosmeceutical products will find excellent market acceptance. Equally exciting are the prospects for major medical innovations that will help find wonderful solutions to a large variety of medical problems. In addition, we are going to be more actively interfacing with the financial community to explain our company and its exciting prospects including the various vertical revenue channels we are developing. I personally expect to begin meeting with investors in the months ahead."
Brunoehler founded Cryobanks International in 1993 and served as its president and CEO until 2008. He set Cryobanks on the path to become one of the world's largest banks for donated unrelated umbilical cord blood. He developed partnerships between Cryobanks International and physicians and hospitals worldwide to further advance the usage of cord blood stem cells for transplant and non-controversial life enhancing research. He was instrumental in assisting state legislators in drafting laws where expectant mothers are educated and informed of the benefits of cord blood donation. He was instrumental in drafting the first state cord blood awareness legislation of its kind in Illinois and Wisconsin.
Brunoehler has put together numerous research and development partnerships to develop therapeutic benefits of cord blood stem cells. He is a past member of The Cord Blood Work Group and the Finance Sub Committees of the World Marrow Donor Association. He has been an active member of the American Society of Hematology and a founding member of the International Cord Blood Society. Brunoehler has lectured in numerous hospitals and universities throughout the world on cord blood donation. He engineered a worldwide network of licensed facilities to grow the inventory and availability of cord blood with the first three locations opened in Athens, Greece, New Delhi, India and Bangkok, Thailand. The Athens location became the first facility in Europe to be accredited by the American Association of Blood Banks. Prior to his work at Cryobanks International, Brunoehler participated in a wide variety of successful ventures. He owned and operated many different businesses and held executive level positions in marketing, public relations and new product development capacities in both established and start-up companies, including seven years with the Bell system. He is a graduate of the University of Central Florida and in 2007 he was the keynote speaker at the commencement celebration for advanced degrees in the health sciences sector.
About AmStem Inc.
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.
there is no news there is nothing in the company read the 10k
the guys from crocs are going to be leaving soon ,they are window dressing.Please tell what is in the company the doctor quit the management has been involved in two other stocks .One was in lawsuits the other is a couple of pennies Google dwight bruenholler sec and you will figure it out .
the guys from crocs are going to be leaving soon .Please tell wha is in the company the doctor quit the management has been involved in two othet stocks .One was in lawsuits the is a couple of pennies Google the dwight bruenholler sec and you will figure it out .
when is the middle going to get closer buy for 40 and sell for 34 dont make sense to me
not true there are about 120 million free trading shares any one can find out by calling the transfer agent!Call them You can find who they are on otcmarkets .com I can only find one 8k for 400k in the filing It says it was 40centc a share when there were 25 million shares in the company Break it down it comes to about 3 cents
about 120 million free can anyone tell me how many free trading shares there are i count please help?I think im right